Figure 5. Anti-CD122 mAb treatment synergizes with an aGITR mAb therapy.

On day +4 post-implantation of B16-OVA, mice were treated with aCD122 or aGITR or the combination as indicated. Mean tumor growth and survival are depicted. Experiments were repeated at least two times. ^*P<0.05; ^**P<0.01; ^***P<0.001; ^****P<0.0001. Errors bars indicate SEM; n = 10/group.